DeepMed Research

West China Hospital of Sichuan University (Sichuan International Hospital)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

Phase 3

Recruiting

Conditions: Rectal Cancer
Neoadjuvant Chemotherapy

Interventions: Drug: Capox chemotherapy

First Posted Date: 2021-06-11

Last Posted Date: 2022-03-31

Lead Sponsor: West China Hospital

Target Recruit Count: 554

Registration Number: NCT04922853

Locations: 🇨🇳
The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
🇨🇳
Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, China
🇨🇳
West China Hospital, Chengdu, Sichuan, China

and more 1 locations

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Pyrotinib combined with albumin-bound paclitaxel and trastuzumab

First Posted Date: 2021-06-08

Last Posted Date: 2022-10-10

Lead Sponsor: West China Hospital

Target Recruit Count: 216

Registration Number: NCT04917900

Locations: 🇨🇳
West China Hospital, Sichuan University, Chengdu, Chengdu, Sichuan, China, China

The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Sintilimab in combination with Multimodality Radiotherapy

First Posted Date: 2021-06-08

Last Posted Date: 2021-06-08

Lead Sponsor: West China Hospital

Target Recruit Count: 28

Registration Number: NCT04917770

The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction

Phase 3

Not yet recruiting

Conditions: STEMI

Interventions: Drug: Sacubitril-Valsartan
Drug: Enalapril
Drug: Valsartan

First Posted Date: 2021-06-03

Last Posted Date: 2021-09-29

Lead Sponsor: West China Hospital

Target Recruit Count: 376

Registration Number: NCT04912167

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer

Phase 2

Conditions: Non-small Cell Lung Cancer
Stage III

Interventions: Drug: tislelizumab

First Posted Date: 2021-04-29

Last Posted Date: 2021-04-29

Lead Sponsor: West China Hospital

Target Recruit Count: 33

Registration Number: NCT04865705

Locations: 🇨🇳
University, Chengdu, Sichuan, China

Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.

Phase 2

Completed

Conditions: Kaposiform Hemangioendothelioma

Interventions: Drug: Sirolimus

First Posted Date: 2021-03-01

Last Posted Date: 2024-05-07

Lead Sponsor: West China Hospital

Target Recruit Count: 79

Registration Number: NCT04775173

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

Optimal Reperfusion Strategy for STEMI Patients With Anticipated PPCI Delay

Not Applicable

Conditions: ST Elevation Myocardial Infarction

Interventions: Other: Reduced-dose facilitated PCI strategy
Other: Pharmacoinvasive strategy

First Posted Date: 2021-02-12

Last Posted Date: 2021-02-12

Lead Sponsor: West China Hospital

Target Recruit Count: 632

Registration Number: NCT04752345

Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate

Phase 2

Not yet recruiting

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Prednisolone
Drug: Goserelin

First Posted Date: 2021-02-03

Last Posted Date: 2021-02-08

Lead Sponsor: West China Hospital

Target Recruit Count: 50

Registration Number: NCT04736108

Locations: 🇨🇳
West China Hospital, Chengdu, Sichuan, China

A Prospective, Multi-center, Real-world Study of Ovarian Metastatic Colorectal Cancer Patients

Recruiting

Conditions: Colorectal Cancer
Ovarian Metastasis

First Posted Date: 2021-01-20

Last Posted Date: 2024-08-06

Lead Sponsor: West China Hospital

Target Recruit Count: 400

Registration Number: NCT04716257

Locations: 🇨🇳
Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
🇨🇳
Sun Yat-sen University Cancer Center, Cantón, Guangdong, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

and more 1 locations

A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)

Conditions: Prostate Cancer Metastatic

First Posted Date: 2020-12-09

Last Posted Date: 2021-05-11

Lead Sponsor: West China Hospital

Target Recruit Count: 100

Registration Number: NCT04660617

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy